Abstract 63P
Background
Pancreatic cancer is highly malignant and has a low cure rate. Traditional treatments are limited, and the potential of immunotherapy remains unrealized due to immune cell heterogeneity in the tumour microenvironment. Tumour-associated macrophages (TAMs), especially tissue-resident macrophages (TRMs), play complex roles in tumours.
Methods
We used single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (bulk-seq) data from pancreatic cancer patients in the GEO and TCGA databases. We analyzed macrophage heterogeneity and their functions in the tumour microenvironment. Using cell communication analysis and immune marker grading, we calculated a TAM score and analyzed survival prognosis, identifying macrophage subpopulations and their roles in tumour progression and immune response.
Results
We characterized the tumour microenvironment using scRNA-seq data and identified the TRM subpopulation. Cell communication analysis revealed interactions, including the CXCL/MIF interaction, between TRMs and various cell populations. TAM score calculations showed that TAM clusters 4, 5, 9, and 10 were significantly associated with survival risk. Predictive analyses for 5-year and 10-year mortality found that TRM cluster 4 had the highest predictive efficacy. Clinical feature analysis of patients with high and low TRM_C4 risk scores revealed significant differences in survival rates, immune cell infiltration, and immune checkpoint expression. Pre- and posttreatment TAM_C4 scores differed significantly between responders and nonresponders, with nonresponders showing increased posttreatment scores and responders showing decreased scores.
Conclusions
This study provides new insights into the heterogeneity of macrophages in pancreatic cancer and their roles in regulating tumour behaviour. Targeting specific macrophage subpopulations may lead to new therapeutic strategies, improving the effectiveness of immunotherapy and the outcomes for patients with pancreatic cancer.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
89P - Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: A systematic review and meta-analysis
Presenter: Huijun Xu
Session: Poster Display session
Resources:
Abstract
90P - Meta-analysis of hypophysitis incidence in melanoma patients treated with immune checkpoint inhibitors
Presenter: Vincas Urbonas
Session: Poster Display session
Resources:
Abstract
91P - Territorial disparities in the use of hospitalization at home for immune checkpoint inhibitors infusion in France between 2021 and 2022
Presenter: Anne Claire Toffart
Session: Poster Display session
Resources:
Abstract
92P - An investigation on the differences between the pre-treatment nutritional and immunological status of nasopharyngeal carcinoma patients and the healthy population
Presenter: Qiao He
Session: Poster Display session
Resources:
Abstract
93P - Pseudoprogression in immunotherapy: Illusion or reality? P-PIT study
Presenter: Amelie Toulet
Session: Poster Display session
Resources:
Abstract
94P - Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
95P - Quality of life (QoL) and care pathway in patients with durable response to immune checkpoint inhibitors (ICI-DR) for advanced or metastatic non-small cell lung cancer (NSCLC) or melanoma: QUALICI study
Presenter: Nicolas Girard
Session: Poster Display session
Resources:
Abstract
96P - Comparative cardiovascular risks of PD-1 vs. PD-L1 inhibitors: A meta-analysis of incidence and severity of cardiotoxicity
Presenter: Mohammedbaqer Al-Ghuraibawi
Session: Poster Display session
Resources:
Abstract
97P - Cardiac risk stratification and serial monitoring during immune checkpoint inhibitor therapy: Prospective real-world experience
Presenter: James Knott
Session: Poster Display session
Resources:
Abstract
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session
Resources:
Abstract